Circulating immune complexes in chronic hepatitis related to hepatitis C and B viruses infection. 1995

J F Tsai, and H S Margolis, and J E Jeng, and M S Ho, and W Y Chang, and Z Y Lin, and J H Tsai
Department of Internal Medicine, Kaohsiung Medical College, Taiwan.

Circulating immune complexes (CIC) may be involved in tissue damage and/or viral clearance in viral hepatitis. To assess the frequency of raised CIC in chronic hepatitis related to hepatitis B and C, IgM, IgG, and hepatitis B surface antigen (HBsAg) containing CIC were determined, by conglutinin (K) and C1q assays, in 101 patients with chronic hepatitis B alone, 24 patients with chronic hepatitis B and C, 48 patients with chronic hepatitis C alone, and 54 healthy controls. Compared to patients with hepatitis B alone, patients with dual infection had higher frequency of raised IgM-C1q CIC (P < 0.001) and IgM-K CIC (P < 0.01). There is no difference in the prevalence of HBsAg-CIC between patients with hepatitis B alone and those with dual infection. Among patients with chronic hepatitis C alone, conglutinin-binding CIC is the predominant type of raised CIC and correlated with more severe liver damage. In conclusion, CIC may play a role in the pathogenesis of chronic hepatitis C virus infection.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D005260 Female Females
D006505 Hepatitis INFLAMMATION of the LIVER. Hepatitides
D006508 Hepatitis Antibodies Immunoglobulins raised by any form of viral hepatitis; some of these antibodies are used to diagnose the specific kind of hepatitis. Antibodies, Hepatitis
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection

Related Publications

J F Tsai, and H S Margolis, and J E Jeng, and M S Ho, and W Y Chang, and Z Y Lin, and J H Tsai
May 1995, Journal of medical virology,
J F Tsai, and H S Margolis, and J E Jeng, and M S Ho, and W Y Chang, and Z Y Lin, and J H Tsai
January 1981, Die Medizinische Welt,
J F Tsai, and H S Margolis, and J E Jeng, and M S Ho, and W Y Chang, and Z Y Lin, and J H Tsai
January 1977, Scandinavian journal of immunology,
J F Tsai, and H S Margolis, and J E Jeng, and M S Ho, and W Y Chang, and Z Y Lin, and J H Tsai
April 1991, Clinical and experimental immunology,
J F Tsai, and H S Margolis, and J E Jeng, and M S Ho, and W Y Chang, and Z Y Lin, and J H Tsai
January 1984, Medecine interne,
J F Tsai, and H S Margolis, and J E Jeng, and M S Ho, and W Y Chang, and Z Y Lin, and J H Tsai
January 1983, Digestion,
J F Tsai, and H S Margolis, and J E Jeng, and M S Ho, and W Y Chang, and Z Y Lin, and J H Tsai
February 1992, Clinical immunology and immunopathology,
J F Tsai, and H S Margolis, and J E Jeng, and M S Ho, and W Y Chang, and Z Y Lin, and J H Tsai
July 1990, Medical laboratory sciences,
J F Tsai, and H S Margolis, and J E Jeng, and M S Ho, and W Y Chang, and Z Y Lin, and J H Tsai
March 1999, Pathologie-biologie,
J F Tsai, and H S Margolis, and J E Jeng, and M S Ho, and W Y Chang, and Z Y Lin, and J H Tsai
May 1995, Medicine,
Copied contents to your clipboard!